About
News
Calendar
Education & Training
Careers
How to Help
Contact Us
My Dana-Farber
Español
Find a Doctor
Get Directions
For Physicians
Make a Gift
Adult Care
Treatment and Care
Treatment Centers and Clinical Services
Care Team
Patient And Family Support
Care Quality and Patient Safety
Patient Stories
For Adult Cancer Survivors
Browse by Cancer Type
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
New Patient Guide
Planning a Visit
Driving Directions
Parking at Dana-Farber
Maps of Dana-Farber
Preparing for Your First Visit
How to Prepare
Talking to Your Doctor
Financial and Legal Matters
Insurance and Financial Assistance
Your Role as Patient
Ethics Consultation
Health Care Proxy
Special Assistance
Interpreters
Patient Navigators
Disability Services
Patient Safety and Advocacy
Safety Information
Patient Relations
Adult Patient and Family Advisory Council
Legislative Action Network
Amenities and Resources
Concierge Services
Appointments & Second Opinions
New Patient?
For appointments or second opinions:
Adults:
(877) 442-DFCI (442-3324)
Children:
(888) PEDI-ONC (733-4662)
or complete the
Appointment Request Form
Online Specialty Consultations
International Patients
Referring Physician?
To refer an adult patient:
(877) 441-DFCI (441-3324)
To refer a pediatric patient:
(888) PEDI-ONC (733-4662)
or complete the
Patient Referral Form
Pediatric Care
Treatment and Care
Pediatric Treatment Centers and Clinical Services
Care Team
Patient And Family Support
Care Quality and Patient Safety
Patient Stories
For Survivors of Childhood Cancer
Browse by Cancer Type
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
New Patient Guide
Planning a Visit
Driving Directions
Parking at Dana-Farber
Maps of Dana-Farber
Preparing for Your First Visit
How to Prepare
Talking to Your Child's Doctor
Financial and Legal Matters
Insurance and Financial Assistance
Your Role as Patient
Ethics Consultation
Health Care Proxy
Special Assistance
Interpreters
Disability Services
Patient Safety and Advocacy
Safety Information
Patient Relations
Legislative Action Network
Pediatric Patient and Family Advisory Council
Amenities and Resources
Concierge Services
Appointments & Second Opinions
New Patient?
For appointments or second opinions:
Adults:
(877) 442-DFCI (442-3324)
Children:
(888) PEDI-ONC (733-4662)
or complete the
Appointment Request Form
Your Child's Care Team
For International Patients
Referring Physician?
To refer an adult patient:
(877) 441-DFCI (441-3324)
To refer a pediatric patient:
(888) PEDI-ONC (733-4662)
or complete the
Patient Referral Form
Research
Clinical Trials
Research Advances
Featured Research
Departments and Centers
Integrative Research Centers
Core Facilities
Research Administration
Technology Transfer
Find a Researcher
Health Library
Blog
Home
Research
Clinical Trials
Clinical Trials by Diagnosis
Pediatric Neuroblastoma Clinical Trials
Showing 1-9 of 9 items
1.
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
The purpose of this study is to compare the pharmacokinetics (blood levels) and safety of chimeric (ch) 14.18 manufactured by two independent drug makers (United Therapeutics [UTC] or the National Cancer Institute [NCI]).
Diagnoses:
Pediatric Oncology
,
Pediatric Neuroblastoma
Status:
Recruiting
2.
Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as fenretinide LXS, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide LXS in treating patients with recurrent, refractory, or persistent neuroblastoma.
Diagnoses:
Pediatric Neuroblastoma
Status:
Recruiting
3.
N99-02: Melphalan and Buthionine Sulfoximine Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Children With Resistant or Recurrent Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of melphalan and buthionine sulfoximine followed by bone marrow or peripheral stem cell transplantation in treating children who have resistant or recurrent neuroblastoma.
Diagnoses:
Pediatric Neuroblastoma
Status:
Recruiting
4.
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as iobenguane I 131, may carry radiation directly to tumor cells and not harm normal cells. Giving vorinostat together with iobenguane I 131 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving vorinostat together with iobenguane I 131 in treating patients with resistant or relapsed neuroblastoma.
Diagnoses:
Pediatric Neuroblastoma
Status:
Recruiting
5.
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
This phase I trial is studying the side effects and the best dose of vorinostat when given together with isotretinoin to see how well it works in treating patients with high-risk refractory or recurrent neuroblastoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Isotretinoin may help vorinostat work better by making tumor cells more sensitive to the drug. Giving vorinostat together with isotretinoin may be an effective treatment for neuroblastoma
Diagnoses:
Pediatric Neuroblastoma
Status:
Recruiting
6.
Ipilimumab in Young Patients With Advanced or Refractory Solid Tumors
RATIONALE: Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of ipilimumab in treating children, adolescents, and young adults with advanced or refractory solid tumors,
Diagnoses:
Pediatric Hodgkin Lymphoma
,
Pediatric Neuroblastoma
,
Pediatric Sarcoma
,
Pediatric Solid Tumors
,
Pediatric Lymphoma
,
Pediatric Wilms' Tumor
Status:
Recruiting
7.
Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma
LEE011 is a small molecule inhibitor of CDK4/6. LEE011 has demonstrated in vitro and in vivo activity in both tumor models. The primary purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) in pediatric patients and to delineate a clinical dose to be used in future studies. This study will also assess the safety, tolerability, PK and preliminary evidence of antitumor activity of LEE011 in patients with MRT or neuroblastoma.
Diagnoses:
Pediatric Brain Tumor
,
Pediatric Neuroblastoma
Status:
Recruiting
8.
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma.
Diagnoses:
Pediatric Neuroblastoma
Status:
Recruiting
9.
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
This treatment study for relapsed high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma involves an autologous cancer testis (CT) antigen specific dendritic cell (DC) vaccine preceded by decitabine as a demethylating chemotherapy.
Diagnoses:
Pediatric Neuroblastoma
Status:
Recruiting
Showing 1-9 of 9 items
Email
Print
Share
Text
Highlight Glossary Terms